开发新的IL-1R对抗剂,提高抗炎功效
Mooseok Kang1, Ae-Ree Lee1, Hyeji Jung2,3
1Cytokine Innovation Center, iProtein Therapeutics Co. Ltd., Industry-University Cooperation Building R7-208, 333 Techno Jungangdae-Ro, Hyeonpoong-Eup, Dalseong-Gun, Daegu 42988, Korea.
Theranostics
|December 22, 2025
概括
工程化Anakinra变种显示增强的抗炎作用,E127Q在降低神经炎症和受体活性方面表现优越. 这一突破为改善针对炎症和神经系统疾病的疗法提供了潜力.
科学领域:
- 生物化学和分子生物学
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
背景情况:
- 阿纳金拉 (hIL-1Ra) 是一种抗炎生物药,其效力和副作用有限.
- 现有疗法需要开发更有效的互白素-1受体 (IL-1R) 反对剂.
- 准IL-1R信号传递对于管理炎症和神经疾病至关重要.
研究的目的:
- 设计具有增强结合稳定性和抗炎功能的新型人间白素-1受体对手 (hIL-1Ra) 变体.
- 在炎症和神经炎症的临床前模型中评估这些变体的疗效.
- 为IL-1R介导疾病确定下一代治疗候选药物.
主要方法:
- 结构引导的突变发生被用来设计六种hIL-1Ra变体.
- 分子动力学模拟预测了变体增强的结合自由能量.
- 细胞培养中的功能性测试和对D301N小鼠的体内研究评估了抗炎和神经保护作用.
主要成果:
- 所有六种工程 hIL-1Ra 变体都表现出改善的抗炎活性,抑制 IL-1β 和 IL-6 mRNA.
- 这种E127Q变体表现出卓越的疗效,有效地抑制IL-1β诱导的神经元中的NMDAR过活化.
- 在体内给予hIL-1Ra E127Q,在慢性神经炎症的小鼠模型中逆转了NMDAR活性升高.
结论:
- 成功开发了下一代hIL-1Ra变体,具有优异的受体结合和抗炎性质.
- 这种E127Q变体代表了减轻炎症和神经炎症反应的有希望的治疗候选者.
- 工程IL-1R抗剂具有治疗一系列系统和神经系统疾病的巨大潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408


